Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Her2-negative Tumor”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT01070706
What this trial is testing

Phase Ib/II Study of Primary Chemotherapy With Paclitaxel, Gemcitabine, and Sunitinib

Who this might be right for
Breast Cancer
Jungsil Ro 15
Testing effectiveness (Phase 2)UnknownNCT01526512
What this trial is testing

Low Dose of Metronomic Cyclophosphamide and Capecitabine in Pretreated HER2-negative Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Fudan University 72
Testing effectiveness (Phase 2)Ended earlyNCT05932667
What this trial is testing

Milademetan and Fulvestrant in GATA3-mutant, ER+HER- Advanced or Metastatic Breast Cancer

Who this might be right for
Advanced or Metastatic Breast Cancer
Institut Curie 1
Very early researchActive Not RecruitingNCT05333874
What this trial is testing

CIPHER Study: Pilot Study to Study the Role of ctDNA in Triple Negative and HER2 Positive Early Stage

Who this might be right for
Breast Cancer, Early-Onset
Rutgers, The State University of New Jersey 34
Early research (Phase 1)Study completedNCT02418624
What this trial is testing

Phase I of Carboplatin-Olaparib Followed by Olaparib Monotherapy in Advanced Cancer

Who this might be right for
Breast CancerOvarian CancerAdvanced Cancer
The Netherlands Cancer Institute 25
Testing effectiveness (Phase 2)Study completedNCT01038804
What this trial is testing

YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Astellas Pharma Inc 101
Testing effectiveness (Phase 2)Study completedNCT01722968
What this trial is testing

A Biomarker Study in Patients With HER2-negative Metastatic Breast Cancer Treated With Bevacizumab and Paclitaxel

Who this might be right for
Breast Cancer
Theodoros Foukakis 33
Early research (Phase 1)Study completedNCT02154776
What this trial is testing

Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer.

Who this might be right for
Advanced or Metastatic Breast Cancer
Novartis Pharmaceuticals 13
Testing effectiveness (Phase 2)Looking for participantsNCT07285382
What this trial is testing

Different Doses of Dalpicicl Combined With Letrozole in the First-line Treatment of HR-positive, HER2-negative Advanced Breast Cancer

Who this might be right for
HR Positive HER2 Negative Advanced Breast Cancer
wanghaibo 120
Not applicableStudy completedNCT00911716
What this trial is testing

TC Avastin. ICORG 08-10, V6

Who this might be right for
Breast Cancer
Cancer Trials Ireland 106
Early research (Phase 1)Active Not RecruitingNCT05143229
What this trial is testing

Alpelisib And Sacituzumab Govitecan For Treatment Of Breast Cancer

Who this might be right for
Breast Cancer
University of Kansas Medical Center 18
Early research (Phase 1)Active Not RecruitingNCT01251874
What this trial is testing

Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer

Who this might be right for
Recurrent Breast CarcinomaStage IIIB Breast Cancer AJCC v7Stage IIIC Breast Cancer AJCC v7+2 more
National Cancer Institute (NCI) 44
Testing effectiveness (Phase 2)Looking for participantsNCT07407920
What this trial is testing

Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial

Who this might be right for
Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Early Stage HER2-Positive Breast Carcinoma+1 more
M.D. Anderson Cancer Center 120
Not applicableStudy completedNCT06705504
What this trial is testing

A Real-world Study of Effectiveness and Safety in HR+/HER2- Breast Cancer Patients Treated With Ribociclib or Alpelisib

Who this might be right for
Hormone Receptor Positive HER-2 Negative Breast Cancer
Novartis 435
Not applicableStudy completedNCT05709158
What this trial is testing

Learn About the Dangers Linked to Myelosuppression (Decreased Bone Marrow Function) in Breast Cancer Patients Treated With the Study Medicine Palbociclib (Pal Bow Sai Klib)

Who this might be right for
Breast Cancer
Pfizer 4,184
Large-scale testing (Phase 3)Active Not RecruitingNCT00070564
What this trial is testing

S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer

Who this might be right for
Breast Cancer
SWOG Cancer Research Network 3,294
Testing effectiveness (Phase 2)Ended earlyNCT03225547
What this trial is testing

Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer

Who this might be right for
Triple Negative Breast NeoplasmsBreast Cancer
University of Chicago 24
Testing effectiveness (Phase 2)Study completedNCT02035813
What this trial is testing

DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs).

Who this might be right for
HER2-negative and Hormone-receptor Positive Metastatic Breast CancerHER2-negative Circulating Tumor CellsPostmenopausal Female Patients
Prof. Wolfgang Janni 116
Testing effectiveness (Phase 2)Ended earlyNCT04142060
What this trial is testing

Targeting the PAM50 Her2-Enriched Phenotype With Enzalutamide in Hormone Receptor-Positive/Her2-Negative Metastatic BC

Who this might be right for
Breast Cancer
SOLTI Breast Cancer Research Group 34
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07101159
What this trial is testing

Dalpiciclib as Adjuvant Therapy for HR-positive/HER2-negative Early-stage Patients

Who this might be right for
Early Breast CancerAdjuvant TherapyHormone Receptor Positive / HER2-negative Breast Cancer
Fujian Cancer Hospital 200
Next Page